Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 21–30 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 21
- Medicine slug
- acitretin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
49 hours
- Numeric value
- 49
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6af396c2-af3e-436d-ba9a-583637495910 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5be620f-d721-40c1-a062-d21c70bfcbed (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e87e415-070d-41f5-9d93-17793e8ad8a6 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08ce9fdd-1e84-4043-b085-91053f975b64 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2150bb0f-551b-4059-a97b-187d3ab22519 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a4ca401-6ea4-4653-8674-056fa637f4a1 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993a5325-cd10-4450-b5ea-1c0a90510df6 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6546625-acb8-460e-b34e-f795bfb3680a (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77011f2b-a2e7-4a43-9ff3-29d73f322319 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85507f6c-f802-479e-bacc-624b5136d092 (opens source in a new tab)
Acitretin label
Version not recorded · Effective date not recorded
The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours).
Projected row 22
- Medicine slug
- acyclovir
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 178
- Source count
- 121
- Agreement rate
- 1
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 121
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 121 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4c5779d-e4bf-4f2b-e053-2995a90a9187 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5a75fa-73db-4f48-895f-de1635d33f49 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68e610a-841c-4b69-9233-673d060561e8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea3e3f6-132d-4b15-ac58-336de05201a7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:785d68bc-0bbf-b69d-e053-2991aa0ac0d5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a9ea291-4ad5-48a8-8c08-5a17c8757549 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6d69697-12bb-4548-a6c3-2463cbf54f8f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7484b631-18f9-440d-bb11-a44932fec6e7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f352a641-988e-4878-8016-2b69cd6ee548 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b600b5d-ce91-461f-b9d1-75b969daf8e9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db35fce0-d7a3-4589-ba60-d78cdb1119cb (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8004652-86fe-4714-81d4-5e1dd2585bb4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960e4ede-692e-4db2-a96e-dc6f4a6190ee (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e580b7e9-9060-43f5-9b58-33998078d7e4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6714cfd9-97d3-4290-b618-54594d89cf4e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b999a9-11cc-d6e5-e053-2995a90a5478 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3cbd634-77c8-3306-bdbd-a4598b20603e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d171c3d-de39-4f82-bacb-3e8d71b16540 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41bea43a-f58c-2c6f-4d31-406ceb456077 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75334fc5-d236-401a-875c-f4f9c7749c1a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4c1305c-f18c-4fb0-83d8-2822341f2dfa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8208711c-18ba-4615-b932-3c0bb7e6efae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fdabab2-bc93-48ab-9c13-d22ec90fdcfc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8a0f9f8-294f-4dd6-bd55-10a6253f1aa8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5b5fd7-64ab-8275-e063-6394a90a2205 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0a0ce5-dc39-4bd3-8b97-21ce9c9999f0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdb7903-0991-413d-b1ad-ab0f1ae2d8f4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38547daa-7d2f-4a7b-84d3-6e164984f958 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc7d67f-35fa-4238-a581-4810645083cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5176c7f9-9076-4797-e054-00144ff8d46c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97ed8713-4b3e-48a9-92c0-0a98ecf0485c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c5d1f30-2d31-417d-860b-7228b7baaa64 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032ce02-e2b3-d426-e063-6294a90ab6c9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cd22728-34b4-4e55-8339-580138fe46d8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acef88f4-6456-4092-993f-27e1496097c7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e203fa9-ee97-1e08-8d6a-fb57cfa13e19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbaf4bf5-57e3-4770-a9b2-d47649e54c1b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0910335b-6796-459f-b97e-d7ef5439a060 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2d9940a-ce88-5fd0-e053-2a95a90a4bc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50c58161-3944-7367-e063-6394a90a6286 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85332671-0e3a-4445-a337-e1266886b9cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b254eed-8ea1-469b-bf27-f5670cd99e8d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fb01f23-e2bd-6850-e053-2995a90a7cc5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4f91376-9e18-41a4-aa5e-adcea0c625d9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad711e4-003d-4b58-8177-32928bc42aa9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55bde35-a202-4c25-b545-e5d5e95c1175 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e5cc54-ed74-3369-e054-00144ff88e88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:968800dc-9456-a45f-e053-2995a90aa15e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada4004a-c10a-6190-e053-2a95a90a5e67 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:290af212-7332-4914-9ef0-65760478fb32 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edb0cd28-ee57-4b60-be94-62c797fbf5e6 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d2a75a5-233f-46dd-9cb0-3918ea53e554 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f56143-ea74-af87-e053-6394a90ae346 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46150f19-ce5d-42a0-80a7-f96fda2b9879 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e78d5e8-ae2d-4e84-b8c2-6765b1299c12 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53cbca4d-3ddc-b11e-e063-6394a90a04fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0de2f5c7-9e75-4bdf-9c28-e026cc6694b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d7994a6-5bd2-494d-89c1-b03755d4f2c3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3efa1e5e-5a14-4724-a2ca-25702f10faed (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e82707-85b6-2fea-e053-2991aa0a99ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f09cdb3f-dfd2-4e47-bb5e-a5d26d8bcc89 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fdeb609-24c4-5024-52c3-6a32bc7f3fcc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d9fea43-6c04-40d7-8aac-398c2de2a558 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:736679be-469e-4bdb-8e15-b10751c3dd60 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58dc1402-6098-9cb3-e063-6294a90a062b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9776b3-a248-e1ea-e053-6294a90aeb7b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677edfd5-2d04-b932-e053-2a91aa0a26b0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e813b35-4ead-42d6-bc51-9d7caf1db1ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1b4142-c5f3-4147-8224-bf6344566694 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51052f0e-1a07-405a-a962-981ce9439e02 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b96e44ca-aa54-4a64-89f4-fb5a5932ceae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0c29e0f-b6e2-49df-88d1-95b7b625d356 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69e5455e-d0be-4c2b-b9ab-458b5480ed57 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5105272f-cff8-8898-e063-6394a90aabb5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1493e22d-455d-b613-e063-6294a90afede (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4729677-164b-41b8-bbc4-4e47346b0f72 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0990b625-5dfe-4810-b5b4-ac5948599e79 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0ed999f-7366-42c3-a6f5-3c239215a99c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37453bcd-e34e-5902-e063-6294a90a0245 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:331fe0bd-6bb2-4337-8faa-d0c82ff54dc7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87c2c1e-568f-49e1-979e-fce80086fe08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3df7fa38-a869-45fb-98a3-81c5a2527d62 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d0e492e-5359-49e8-812d-8c8e2e5d42f8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e7b340-0635-2595-e053-2a91aa0ad266 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37761c4f-4378-472e-a41b-6a1d40575cb7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2757bb30-3374-4e1b-b496-14874f7ec623 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7fd298b-3914-4316-8484-2d3ae188221a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8433261-07f1-448b-aaf4-631414598c08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e186fdc9-b60e-4280-8d60-36cae9f2838f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89583890-186b-4a7a-8741-41f6c5f0a99d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:395cd839-21e1-43e2-a8ce-078f07bc7668 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e6a3667-af06-40de-80c0-8c4346e0671f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:864d96b9-e2de-45a8-850b-6f7b72ceefe1 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:499c6a98-0614-4ded-8526-909942bae8a4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da5a809c-6ddc-4609-9a34-ccb3d2d43976 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:638803d2-a172-486d-e053-2991aa0ab074 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32aa3f42-23a1-4867-8228-e6e76cf9f135 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d824fc07-9f03-4cb2-9bf8-ff7cc2955255 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8de9c4f3-b800-4419-a063-8b62a0cba0fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ca1395f-96b4-4543-8eed-bd07c62bbc7c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0e41bf9-e141-404e-9952-aeeb705958b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c46d5033-b1b2-e213-e053-2995a90ae6a3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f17e6f-63c7-4828-8585-91fc582df30b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cacaeb2a-6d3b-cf3e-e053-2a95a90a6ce4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdbea8d-29df-0045-e063-6294a90a9506 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0908b3c-f5dd-4113-9080-bb01abe13c9c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c818e86c-a4d0-48cd-a888-fa1ee9e2aa19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1744e01-0e40-4851-8ffc-c3bf29dd7c2b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8542495c-eef1-448b-abb5-83cb1ac589f7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5356160-cb35-4ff6-91d5-2ade594e0279 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86c43bdf-c5bf-47cd-8dfd-811263825878 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40a57b9-4cf1-4a69-abf3-eb99a7fcda00 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5b3a11-9c4b-4998-8a18-3046af1314ab (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3da54b2d-a206-4ff5-8cc2-90762c4fd70d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e6b1ad-810b-4f53-b92a-b28fc2111f3f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2ae0432-bd2a-1480-e053-2a95a90a6fc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33630a35-346e-43b6-9286-89e28ac0094a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2 .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfee4476-a3c9-4e0c-a235-c68c5d46931e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dcfd21c-43f0-469c-be70-a4e74e6ccf88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05f42300-2a06-45f1-a9b9-6e5c84ae58ec (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7317324-4654-4bcc-8edf-7b7cd8794d2e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with
Projected row 23
- Medicine slug
- acyclovir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 178
- Source count
- 133
- Agreement rate
- 1
- Recorded readings
2.5 to 3.3 hr
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 133
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 133 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1086845-ba08-4fb2-81dc-aea9c68bf2c3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4c5779d-e4bf-4f2b-e053-2995a90a9187 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5a75fa-73db-4f48-895f-de1635d33f49 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68e610a-841c-4b69-9233-673d060561e8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea3e3f6-132d-4b15-ac58-336de05201a7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:785d68bc-0bbf-b69d-e053-2991aa0ac0d5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a9ea291-4ad5-48a8-8c08-5a17c8757549 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6d69697-12bb-4548-a6c3-2463cbf54f8f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b24201ea-aeae-4de1-b01b-eee89068e786 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7484b631-18f9-440d-bb11-a44932fec6e7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f352a641-988e-4878-8016-2b69cd6ee548 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b600b5d-ce91-461f-b9d1-75b969daf8e9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db35fce0-d7a3-4589-ba60-d78cdb1119cb (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e99a6b-79a6-7fdb-e053-2a95a90a8563 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8004652-86fe-4714-81d4-5e1dd2585bb4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960e4ede-692e-4db2-a96e-dc6f4a6190ee (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e580b7e9-9060-43f5-9b58-33998078d7e4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6714cfd9-97d3-4290-b618-54594d89cf4e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b999a9-11cc-d6e5-e053-2995a90a5478 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3cbd634-77c8-3306-bdbd-a4598b20603e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d171c3d-de39-4f82-bacb-3e8d71b16540 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41bea43a-f58c-2c6f-4d31-406ceb456077 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75334fc5-d236-401a-875c-f4f9c7749c1a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4c1305c-f18c-4fb0-83d8-2822341f2dfa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8208711c-18ba-4615-b932-3c0bb7e6efae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fdabab2-bc93-48ab-9c13-d22ec90fdcfc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8a0f9f8-294f-4dd6-bd55-10a6253f1aa8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5b5fd7-64ab-8275-e063-6394a90a2205 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0a0ce5-dc39-4bd3-8b97-21ce9c9999f0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdb7903-0991-413d-b1ad-ab0f1ae2d8f4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38547daa-7d2f-4a7b-84d3-6e164984f958 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc7d67f-35fa-4238-a581-4810645083cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5176c7f9-9076-4797-e054-00144ff8d46c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97ed8713-4b3e-48a9-92c0-0a98ecf0485c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c5d1f30-2d31-417d-860b-7228b7baaa64 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032ce02-e2b3-d426-e063-6294a90ab6c9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cd22728-34b4-4e55-8339-580138fe46d8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acef88f4-6456-4092-993f-27e1496097c7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e203fa9-ee97-1e08-8d6a-fb57cfa13e19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbaf4bf5-57e3-4770-a9b2-d47649e54c1b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0910335b-6796-459f-b97e-d7ef5439a060 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2d9940a-ce88-5fd0-e053-2a95a90a4bc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50c58161-3944-7367-e063-6394a90a6286 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85332671-0e3a-4445-a337-e1266886b9cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b254eed-8ea1-469b-bf27-f5670cd99e8d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fb01f23-e2bd-6850-e053-2995a90a7cc5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4f91376-9e18-41a4-aa5e-adcea0c625d9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad711e4-003d-4b58-8177-32928bc42aa9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55bde35-a202-4c25-b545-e5d5e95c1175 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e5cc54-ed74-3369-e054-00144ff88e88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:968800dc-9456-a45f-e053-2995a90aa15e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada4004a-c10a-6190-e053-2a95a90a5e67 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:290af212-7332-4914-9ef0-65760478fb32 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:713960c2-8278-4778-b781-08ec89a9cfce (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edb0cd28-ee57-4b60-be94-62c797fbf5e6 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d2a75a5-233f-46dd-9cb0-3918ea53e554 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f56143-ea74-af87-e053-6394a90ae346 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46150f19-ce5d-42a0-80a7-f96fda2b9879 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e78d5e8-ae2d-4e84-b8c2-6765b1299c12 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53cbca4d-3ddc-b11e-e063-6394a90a04fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0de2f5c7-9e75-4bdf-9c28-e026cc6694b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d7994a6-5bd2-494d-89c1-b03755d4f2c3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34a38cdf-04e8-4006-a9f5-4a0831117d61 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3efa1e5e-5a14-4724-a2ca-25702f10faed (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e82707-85b6-2fea-e053-2991aa0a99ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f09cdb3f-dfd2-4e47-bb5e-a5d26d8bcc89 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:116f4f0d-66c5-49dd-e063-6394a90ab2b5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fdeb609-24c4-5024-52c3-6a32bc7f3fcc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d9fea43-6c04-40d7-8aac-398c2de2a558 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:736679be-469e-4bdb-8e15-b10751c3dd60 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58dc1402-6098-9cb3-e063-6294a90a062b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9776b3-a248-e1ea-e053-6294a90aeb7b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1033fda-8242-4006-b1cd-23474d70671f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677edfd5-2d04-b932-e053-2a91aa0a26b0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e813b35-4ead-42d6-bc51-9d7caf1db1ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1b4142-c5f3-4147-8224-bf6344566694 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51052f0e-1a07-405a-a962-981ce9439e02 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b96e44ca-aa54-4a64-89f4-fb5a5932ceae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0c29e0f-b6e2-49df-88d1-95b7b625d356 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69e5455e-d0be-4c2b-b9ab-458b5480ed57 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5105272f-cff8-8898-e063-6394a90aabb5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1493e22d-455d-b613-e063-6294a90afede (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4729677-164b-41b8-bbc4-4e47346b0f72 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0990b625-5dfe-4810-b5b4-ac5948599e79 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0ed999f-7366-42c3-a6f5-3c239215a99c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37453bcd-e34e-5902-e063-6294a90a0245 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:331fe0bd-6bb2-4337-8faa-d0c82ff54dc7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87c2c1e-568f-49e1-979e-fce80086fe08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387d33ed-45e5-42d6-e063-6294a90afbb7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 %* *Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3df7fa38-a869-45fb-98a3-81c5a2527d62 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d0e492e-5359-49e8-812d-8c8e2e5d42f8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e7b340-0635-2595-e053-2a91aa0ad266 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37761c4f-4378-472e-a41b-6a1d40575cb7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2757bb30-3374-4e1b-b496-14874f7ec623 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e73ae5c8-7a77-4330-817d-482d1de4e994 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7fd298b-3914-4316-8484-2d3ae188221a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8433261-07f1-448b-aaf4-631414598c08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e186fdc9-b60e-4280-8d60-36cae9f2838f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89583890-186b-4a7a-8741-41f6c5f0a99d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:395cd839-21e1-43e2-a8ce-078f07bc7668 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e6a3667-af06-40de-80c0-8c4346e0671f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:864d96b9-e2de-45a8-850b-6f7b72ceefe1 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:499c6a98-0614-4ded-8526-909942bae8a4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da5a809c-6ddc-4609-9a34-ccb3d2d43976 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:638803d2-a172-486d-e053-2991aa0ab074 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32aa3f42-23a1-4867-8228-e6e76cf9f135 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d824fc07-9f03-4cb2-9bf8-ff7cc2955255 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8de9c4f3-b800-4419-a063-8b62a0cba0fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ca1395f-96b4-4543-8eed-bd07c62bbc7c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0e41bf9-e141-404e-9952-aeeb705958b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c46d5033-b1b2-e213-e053-2995a90ae6a3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f17e6f-63c7-4828-8585-91fc582df30b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cacaeb2a-6d3b-cf3e-e053-2a95a90a6ce4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdbea8d-29df-0045-e063-6294a90a9506 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:067109d0-2539-42b6-9e95-102b58ca54dc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0908b3c-f5dd-4113-9080-bb01abe13c9c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c818e86c-a4d0-48cd-a888-fa1ee9e2aa19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1744e01-0e40-4851-8ffc-c3bf29dd7c2b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8542495c-eef1-448b-abb5-83cb1ac589f7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5356160-cb35-4ff6-91d5-2ade594e0279 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37a51d9c-1f39-4065-8c7d-6528ac6de91c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86c43bdf-c5bf-47cd-8dfd-811263825878 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40a57b9-4cf1-4a69-abf3-eb99a7fcda00 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5b3a11-9c4b-4998-8a18-3046af1314ab (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3da54b2d-a206-4ff5-8cc2-90762c4fd70d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e6b1ad-810b-4f53-b92a-b28fc2111f3f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f1db9f0-9b41-4fb7-8798-44fdc2c128df (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2ae0432-bd2a-1480-e053-2a95a90a6fc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33630a35-346e-43b6-9286-89e28ac0094a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2 .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfee4476-a3c9-4e0c-a235-c68c5d46931e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dcfd21c-43f0-469c-be70-a4e74e6ccf88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05f42300-2a06-45f1-a9b9-6e5c84ae58ec (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7317324-4654-4bcc-8edf-7b7cd8794d2e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with
Projected row 24
- Medicine slug
- acyclovir
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 178
- Source count
- 142
- Agreement rate
- 1
- Recorded readings
9 %
- Numeric value
- 9
- Unit
- %
- Source records
- 142
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 142 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1086845-ba08-4fb2-81dc-aea9c68bf2c3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4c5779d-e4bf-4f2b-e053-2995a90a9187 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5a75fa-73db-4f48-895f-de1635d33f49 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68e610a-841c-4b69-9233-673d060561e8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea3e3f6-132d-4b15-ac58-336de05201a7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:785d68bc-0bbf-b69d-e053-2991aa0ac0d5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a9ea291-4ad5-48a8-8c08-5a17c8757549 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6d69697-12bb-4548-a6c3-2463cbf54f8f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b24201ea-aeae-4de1-b01b-eee89068e786 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7484b631-18f9-440d-bb11-a44932fec6e7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f352a641-988e-4878-8016-2b69cd6ee548 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b600b5d-ce91-461f-b9d1-75b969daf8e9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db35fce0-d7a3-4589-ba60-d78cdb1119cb (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e99a6b-79a6-7fdb-e053-2a95a90a8563 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8004652-86fe-4714-81d4-5e1dd2585bb4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960e4ede-692e-4db2-a96e-dc6f4a6190ee (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e580b7e9-9060-43f5-9b58-33998078d7e4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6714cfd9-97d3-4290-b618-54594d89cf4e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69a98000-adef-4323-89a7-09e035a257d4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b999a9-11cc-d6e5-e053-2995a90a5478 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae921e4e-b8ae-4a45-acc1-32e5e719812b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3cbd634-77c8-3306-bdbd-a4598b20603e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d171c3d-de39-4f82-bacb-3e8d71b16540 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41bea43a-f58c-2c6f-4d31-406ceb456077 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75334fc5-d236-401a-875c-f4f9c7749c1a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4c1305c-f18c-4fb0-83d8-2822341f2dfa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8208711c-18ba-4615-b932-3c0bb7e6efae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fdabab2-bc93-48ab-9c13-d22ec90fdcfc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8a0f9f8-294f-4dd6-bd55-10a6253f1aa8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5b5fd7-64ab-8275-e063-6394a90a2205 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0a0ce5-dc39-4bd3-8b97-21ce9c9999f0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdb7903-0991-413d-b1ad-ab0f1ae2d8f4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38547daa-7d2f-4a7b-84d3-6e164984f958 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc7d67f-35fa-4238-a581-4810645083cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5176c7f9-9076-4797-e054-00144ff8d46c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97ed8713-4b3e-48a9-92c0-0a98ecf0485c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c5d1f30-2d31-417d-860b-7228b7baaa64 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4032ce02-e2b3-d426-e063-6294a90ab6c9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cd22728-34b4-4e55-8339-580138fe46d8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acef88f4-6456-4092-993f-27e1496097c7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e203fa9-ee97-1e08-8d6a-fb57cfa13e19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbaf4bf5-57e3-4770-a9b2-d47649e54c1b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0910335b-6796-459f-b97e-d7ef5439a060 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2d9940a-ce88-5fd0-e053-2a95a90a4bc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50c58161-3944-7367-e063-6394a90a6286 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85332671-0e3a-4445-a337-e1266886b9cf (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b254eed-8ea1-469b-bf27-f5670cd99e8d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fb01f23-e2bd-6850-e053-2995a90a7cc5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4f91376-9e18-41a4-aa5e-adcea0c625d9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ad711e4-003d-4b58-8177-32928bc42aa9 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55bde35-a202-4c25-b545-e5d5e95c1175 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e5cc54-ed74-3369-e054-00144ff88e88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:968800dc-9456-a45f-e053-2995a90aa15e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada4004a-c10a-6190-e053-2a95a90a5e67 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:290af212-7332-4914-9ef0-65760478fb32 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:713960c2-8278-4778-b781-08ec89a9cfce (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edb0cd28-ee57-4b60-be94-62c797fbf5e6 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d2a75a5-233f-46dd-9cb0-3918ea53e554 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f56143-ea74-af87-e053-6394a90ae346 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46150f19-ce5d-42a0-80a7-f96fda2b9879 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e78d5e8-ae2d-4e84-b8c2-6765b1299c12 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53cbca4d-3ddc-b11e-e063-6394a90a04fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0de2f5c7-9e75-4bdf-9c28-e026cc6694b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d7994a6-5bd2-494d-89c1-b03755d4f2c3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34a38cdf-04e8-4006-a9f5-4a0831117d61 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3efa1e5e-5a14-4724-a2ca-25702f10faed (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e82707-85b6-2fea-e053-2991aa0a99ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f09cdb3f-dfd2-4e47-bb5e-a5d26d8bcc89 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:116f4f0d-66c5-49dd-e063-6394a90ab2b5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fdeb609-24c4-5024-52c3-6a32bc7f3fcc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d9fea43-6c04-40d7-8aac-398c2de2a558 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:badf347b-eeee-4239-9c74-966f262925aa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:736679be-469e-4bdb-8e15-b10751c3dd60 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58dc1402-6098-9cb3-e063-6294a90a062b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9776b3-a248-e1ea-e053-6294a90aeb7b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1033fda-8242-4006-b1cd-23474d70671f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677edfd5-2d04-b932-e053-2a91aa0a26b0 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e813b35-4ead-42d6-bc51-9d7caf1db1ef (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1b4142-c5f3-4147-8224-bf6344566694 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51052f0e-1a07-405a-a962-981ce9439e02 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b96e44ca-aa54-4a64-89f4-fb5a5932ceae (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0c29e0f-b6e2-49df-88d1-95b7b625d356 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69e5455e-d0be-4c2b-b9ab-458b5480ed57 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5105272f-cff8-8898-e063-6394a90aabb5 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1493e22d-455d-b613-e063-6294a90afede (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:babdbce2-5cbd-4943-bc38-9ebdd696a77a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4729677-164b-41b8-bbc4-4e47346b0f72 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0990b625-5dfe-4810-b5b4-ac5948599e79 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0ed999f-7366-42c3-a6f5-3c239215a99c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37453bcd-e34e-5902-e063-6294a90a0245 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:331fe0bd-6bb2-4337-8faa-d0c82ff54dc7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87c2c1e-568f-49e1-979e-fce80086fe08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb64dfab-52ee-4312-bc9c-c3d04efe9109 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387d33ed-45e5-42d6-e063-6294a90afbb7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 %* *Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3df7fa38-a869-45fb-98a3-81c5a2527d62 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d0e492e-5359-49e8-812d-8c8e2e5d42f8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e7b340-0635-2595-e053-2a91aa0ad266 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37761c4f-4378-472e-a41b-6a1d40575cb7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2757bb30-3374-4e1b-b496-14874f7ec623 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* * Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e73ae5c8-7a77-4330-817d-482d1de4e994 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7fd298b-3914-4316-8484-2d3ae188221a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8433261-07f1-448b-aaf4-631414598c08 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e186fdc9-b60e-4280-8d60-36cae9f2838f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89583890-186b-4a7a-8741-41f6c5f0a99d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:395cd839-21e1-43e2-a8ce-078f07bc7668 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e6a3667-af06-40de-80c0-8c4346e0671f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:864d96b9-e2de-45a8-850b-6f7b72ceefe1 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:499c6a98-0614-4ded-8526-909942bae8a4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da5a809c-6ddc-4609-9a34-ccb3d2d43976 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n=23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:638803d2-a172-486d-e053-2991aa0ab074 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32aa3f42-23a1-4867-8228-e6e76cf9f135 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d824fc07-9f03-4cb2-9bf8-ff7cc2955255 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8de9c4f3-b800-4419-a063-8b62a0cba0fa (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:889bccd1-3793-40ce-bca2-c8c9cf6b7488 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ca1395f-96b4-4543-8eed-bd07c62bbc7c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0e41bf9-e141-404e-9952-aeeb705958b4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c46d5033-b1b2-e213-e053-2995a90ae6a3 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f17e6f-63c7-4828-8585-91fc582df30b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown inTable 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1bb347d-74f4-4976-8450-a375a271718f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cacaeb2a-6d3b-cf3e-e053-2a95a90a6ce4 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdbea8d-29df-0045-e063-6294a90a9506 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:067109d0-2539-42b6-9e95-102b58ca54dc (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0908b3c-f5dd-4113-9080-bb01abe13c9c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3ab226c-677d-4cb7-85cb-1c2e5012f40d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23a7cf9e-f21b-06c2-e063-6394a90aa623 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c818e86c-a4d0-48cd-a888-fa1ee9e2aa19 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1744e01-0e40-4851-8ffc-c3bf29dd7c2b (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8542495c-eef1-448b-abb5-83cb1ac589f7 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5356160-cb35-4ff6-91d5-2ade594e0279 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37a51d9c-1f39-4065-8c7d-6528ac6de91c (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86c43bdf-c5bf-47cd-8dfd-811263825878 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40a57b9-4cf1-4a69-abf3-eb99a7fcda00 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e5b3a11-9c4b-4998-8a18-3046af1314ab (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3da54b2d-a206-4ff5-8cc2-90762c4fd70d (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e6b1ad-810b-4f53-b92a-b28fc2111f3f (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f1db9f0-9b41-4fb7-8798-44fdc2c128df (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9 % to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bio availability 10 % to 20 % * * Bio availability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2ae0432-bd2a-1480-e053-2a95a90a6fc8 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Table 1: Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 h Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33630a35-346e-43b6-9286-89e28ac0094a (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2 .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfee4476-a3c9-4e0c-a235-c68c5d46931e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% * In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dcfd21c-43f0-469c-be70-a4e74e6ccf88 (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elemination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05f42300-2a06-45f1-a9b9-6e5c84ae58ec (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% Bioavailability decreases with increasing dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7317324-4654-4bcc-8edf-7b7cd8794d2e (opens source in a new tab)
Acyclovir label
Version not recorded · Effective date not recorded
Acyclovir Pharmacokinetic Characteristics (Range) Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* *Bioavailability decreases with increasing dose In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with
Projected row 25
- Medicine slug
- adalimumab-adaz
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3468792f-63ef-4916-8ed1-8214f327d9dd (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e303a4a-980b-4f2a-9d03-786928758637 (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac7d061-3380-468c-b077-c05f8dfbc829 (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
Projected row 26
- Medicine slug
- adalimumab-adaz
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
10 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3468792f-63ef-4916-8ed1-8214f327d9dd (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e303a4a-980b-4f2a-9d03-786928758637 (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac7d061-3380-468c-b077-c05f8dfbc829 (opens source in a new tab)
Adalimumab-Adaz label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
Projected row 27
- Medicine slug
- adalimumab-aqvh
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd0e7af2-7704-49ce-bde9-f645294b6788 (opens source in a new tab)
Adalimumab-Aqvh label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cab600d-6950-409f-a6d8-d447da22cd95 (opens source in a new tab)
Adalimumab-Aqvh label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
Projected row 28
- Medicine slug
- adalimumab-aqvh
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
10 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd0e7af2-7704-49ce-bde9-f645294b6788 (opens source in a new tab)
Adalimumab-Aqvh label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cab600d-6950-409f-a6d8-d447da22cd95 (opens source in a new tab)
Adalimumab-Aqvh label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
Projected row 29
- Medicine slug
- adalimumab-atto
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c44bd5b-4464-40a4-8933-8680950f00f2 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7862491-2634-4402-b001-dcc1abf8dd58 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7178e36-6787-45ab-8fee-be59bc6a4aa4 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
Absorption The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%.
Projected row 30
- Medicine slug
- adalimumab-atto
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
10 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c44bd5b-4464-40a4-8933-8680950f00f2 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7862491-2634-4402-b001-dcc1abf8dd58 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7178e36-6787-45ab-8fee-be59bc6a4aa4 (opens source in a new tab)
Adalimumab-Atto label
Version not recorded · Effective date not recorded
The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=20Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.